Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a research note issued to investors on Saturday.
Several other analysts have also recently weighed in on the company. Weiss Ratings cut Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. decreased their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Finally, Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of “Buy” and an average target price of $18.75.
Read Our Latest Stock Report on Lexeo Therapeutics
Lexeo Therapeutics Price Performance
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Equities analysts anticipate that Lexeo Therapeutics will post -1.2 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Narinder Pal Bhalla sold 22,306 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the sale, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. The trade was a 21.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $116,242.56. Following the sale, the chief executive officer directly owned 377,817 shares in the company, valued at $1,692,620.16. This represents a 6.43% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 57,560 shares of company stock worth $256,577. Company insiders own 2.00% of the company’s stock.
Institutional Trading of Lexeo Therapeutics
A number of institutional investors have recently modified their holdings of the stock. Allworth Financial LP grew its holdings in shares of Lexeo Therapeutics by 1,002.9% during the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after purchasing an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after purchasing an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Lexeo Therapeutics in the fourth quarter valued at about $37,000. California State Teachers Retirement System lifted its position in Lexeo Therapeutics by 123.7% during the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in Lexeo Therapeutics by 160.2% during the fourth quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company’s stock worth $58,000 after purchasing an additional 3,615 shares during the period. 60.67% of the stock is currently owned by institutional investors.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.
The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.
Read More
- Five stocks we like better than Lexeo Therapeutics
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
